Suppressing proteasome mediated processing of Topoisomerase II DNA-protein complexes preserves genome integrity

Abstract

Topoisomerase II (TOP2) relieves topological stress in DNA by introducing double-strand breaks (DSBs) via a transient, covalently linked TOP2 DNA-protein intermediate, termed TOP2 cleavage complex (TOP2cc). TOP2ccs are normally rapidly reversible, but can be stabilized by TOP2 poisons, such as the chemotherapeutic agent etoposide (ETO). TOP2 poisons have shown significant variability in their therapeutic effectiveness across different cancers for reasons that remain to be determined. One potential explanation for the differential cellular response to these drugs is in the manner by which cells process TOP2ccs. Cells are thought to remove TOP2ccs primarily by proteolytic degradation followed by DNA DSB repair. Here, we show that proteasome-mediated repair of TOP2cc is highly error-prone. Pre-treating primary splenic mouse B-cells with proteasome inhibitors prevented the proteolytic processing of trapped TOP2ccs, suppressed the DNA damage response (DDR) and completely protected cells from ETO-induced genome instability, thereby preserving cellular viability. When degradation of TOP2cc was suppressed, the TOP2 enzyme uncoupled itself from the DNA following ETO washout, in an error-free manner. This suggests a potential mechanism of developing resistance to topoisomerase poisons by ensuring rapid TOP2cc reversal.

Data availability

Sequencing data has been deposited in GEO under the accession code GSE140372

The following data sets were generated

Article and author information

Author details

  1. Nicholas Sciascia

    Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4169-4929
  2. Wei Wu

    Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Dali Zong

    Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Yilun Sun

    Developmental Therapeutics Branch, National Cancer Institute, NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Nancy Wong

    Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Sam John

    Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Darawalee Wangsa

    Genetics Branch, National Cancer Institute, NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Thomas Ried

    Genetics Branch, National Cancer Institute, NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Samuel F Bunting

    Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Yves Pommier

    Developmental Therapeutics Branch, National Cancer Institute, NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. André Nussenzweig

    Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, United States
    For correspondence
    andre_nussenzweig@nih.gov
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8952-7268

Funding

National Institutes of Health (Intramural Research Program)

  • André Nussenzweig

Ellison Medical Foundation (Senior Scholar in Aging Award AG-SS- 2633-11)

  • André Nussenzweig

Department of Defense Idea Expansion Award (W81XWH-15-2-006)

  • André Nussenzweig

Department of Defense Idea Breakthrough Award (W81XWH-16-1-599)

  • André Nussenzweig

Alex Lemonade Stand Foundation Award

  • André Nussenzweig

National Institutes of Health (Intramural FLEX Award)

  • André Nussenzweig

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All mouse breeding and experimentation followed protocols approved by the National Institutes of Health Institutional Animal Care and Use Committee (Protocol Numbers: EIB-064-3 and 17-042).

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 3,044
    views
  • 508
    downloads
  • 32
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Nicholas Sciascia
  2. Wei Wu
  3. Dali Zong
  4. Yilun Sun
  5. Nancy Wong
  6. Sam John
  7. Darawalee Wangsa
  8. Thomas Ried
  9. Samuel F Bunting
  10. Yves Pommier
  11. André Nussenzweig
(2020)
Suppressing proteasome mediated processing of Topoisomerase II DNA-protein complexes preserves genome integrity
eLife 9:e53447.
https://doi.org/10.7554/eLife.53447

Share this article

https://doi.org/10.7554/eLife.53447

Further reading

    1. Computational and Systems Biology
    2. Genetics and Genomics
    Daniel Hui, Scott Dudek ... Marylyn D Ritchie
    Research Article

    Apart from ancestry, personal or environmental covariates may contribute to differences in polygenic score (PGS) performance. We analyzed the effects of covariate stratification and interaction on body mass index (BMI) PGS (PGSBMI) across four cohorts of European (N = 491,111) and African (N = 21,612) ancestry. Stratifying on binary covariates and quintiles for continuous covariates, 18/62 covariates had significant and replicable R2 differences among strata. Covariates with the largest differences included age, sex, blood lipids, physical activity, and alcohol consumption, with R2 being nearly double between best- and worst-performing quintiles for certain covariates. Twenty-eight covariates had significant PGSBMI–covariate interaction effects, modifying PGSBMI effects by nearly 20% per standard deviation change. We observed overlap between covariates that had significant R2 differences among strata and interaction effects – across all covariates, their main effects on BMI were correlated with their maximum R2 differences and interaction effects (0.56 and 0.58, respectively), suggesting high-PGSBMI individuals have highest R2 and increase in PGS effect. Using quantile regression, we show the effect of PGSBMI increases as BMI itself increases, and that these differences in effects are directly related to differences in R2 when stratifying by different covariates. Given significant and replicable evidence for context-specific PGSBMI performance and effects, we investigated ways to increase model performance taking into account nonlinear effects. Machine learning models (neural networks) increased relative model R2 (mean 23%) across datasets. Finally, creating PGSBMI directly from GxAge genome-wide association studies effects increased relative R2 by 7.8%. These results demonstrate that certain covariates, especially those most associated with BMI, significantly affect both PGSBMI performance and effects across diverse cohorts and ancestries, and we provide avenues to improve model performance that consider these effects.

    1. Genetics and Genomics
    Shuai Zhang, Ruixue Wang ... Lin Sun
    Research Article

    N6-methyladenosine (m6A) in eukaryotic RNA is an epigenetic modification that is critical for RNA metabolism, gene expression regulation, and the development of organisms. Aberrant expression of m6A components appears in a variety of human diseases. RNA m6A modification in Drosophila has proven to be involved in sex determination regulated by Sxl and may affect X chromosome expression through the MSL complex. The dosage-related effects under the condition of genomic imbalance (i.e. aneuploidy) are related to various epigenetic regulatory mechanisms. Here, we investigated the roles of RNA m6A modification in unbalanced genomes using aneuploid Drosophila. The results showed that the expression of m6A components changed significantly under genomic imbalance, and affected the abundance and genome-wide distribution of m6A, which may be related to the developmental abnormalities of aneuploids. The relationships between methylation status and classical dosage effect, dosage compensation, and inverse dosage effect were also studied. In addition, we demonstrated that RNA m6A methylation may affect dosage-dependent gene regulation through dosage-sensitive modifiers, alternative splicing, the MSL complex, and other processes. More interestingly, there seems to be a close relationship between MSL complex and RNA m6A modification. It is found that ectopically overexpressed MSL complex, especially the levels of H4K16Ac through MOF, could influence the expression levels of m6A modification and genomic imbalance may be involved in this interaction. We found that m6A could affect the levels of H4K16Ac through MOF, a component of the MSL complex, and that genomic imbalance may be involved in this interaction. Altogether, our work reveals the dynamic and regulatory role of RNA m6A modification in unbalanced genomes, and may shed new light on the mechanisms of aneuploidy-related developmental abnormalities and diseases.